The effects of estrogen therapy and estrogen combined with different androgenic progestins on carbohydrate and lipid metabolism in overweight–obese younger postmenopausal women
article
OA: closed
CC0
⤵ 1 in-corpus citation
Abstract
OBJECTIVE: The aim of the present study was to compare the effect of three different progestins with differing androgenicity on carbohydrate and lipid metabolism in overweight-obese younger postmenopausal women. Additionally, the relationship between testosterone and insulin resistance was assessed. METHODS: The study included 125 postmenopausal women. Estradiol (E(2)) 2 mg/day was given to 20 hysterectomized women and the remaining 105 women were randomized into three treatment groups: E(2) 2 mg/day plus dienogest 2 mg/day (n=35); E(2) 2 mg/day plus norethisterone acetate (NETA) 1 mg/day (n=35); E(2) 2 mg/day plus medroxyprogesterone acetate (MPA) 2.5 mg/day (n=35). A 75-g oral glucose tolerance test was performed at the initial and 3-month visit. Serum glucose, insulin, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides were measured before and after treatment. RESULTS: A significant treatment-related increase was observed only in the E(2)/MPA group for insulin resistance (p=0.031). When the change in the insulin/glucose ratio was compared, the E(2) group was significantly different from the E(2)/MPA and E(2)/NETA groups (p=0.008 and 0.02, respectively). Only the E(2)/dienogest group showed a treatment-related increase in fasting glucose level (p=0.037). A decrease in total cholesterol and LDL-C levels was observed in all groups (p=0.004 and 0.012, respectively). The only significant decrease in HDL-C level was observed in the E(2)/NETA group (p=0.005). CONCLUSION: Estrogen therapy had a positive effect on carbohydrate and lipid metabolism in overweight-obese postmenopausal women. The addition of progestin to estrogen therapy attenuated estrogen's positive effects slightly; however, the biological actions of the three different androgenic progestins used did not result in any variation.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (1)
References (35)
- doi:10.7326/0003-4819-138-1-200301070-00005 via openalex
- W52369245 via openalex
- doi:10.1093/oxfordjournals.aje.a009100 via openalex
- doi:10.2337/diacare.21.10.1589 via openalex
- doi:10.1007/s001250050758 via openalex
- doi:10.1093/fampra/17.6.497 via openalex
- doi:10.1016/0026-0495(93)90058-v via openalex
- doi:10.1046/j.1365-2796.1996.505833000.x via openalex
- doi:10.1038/sj.ijo.0801850 via openalex
- doi:10.1210/jc.2004-1479 via openalex
- doi:10.1089/jwh.2005.14.137 via openalex
- doi:10.1152/ajpendo.1993.264.3.e450 via openalex
- W2342815157 via openalex
- W2604297399 via openalex
- doi:10.1016/s0002-9378(96)70111-4 via openalex
- doi:10.1210/endo-121-4-1366 via openalex
- doi:10.2337/diacare.25.1.127 via openalex
- doi:10.1210/endo-117-4-1336 via openalex
- doi:10.1210/jcem.82.12.4443 via openalex
- doi:10.1093/aje/kwh250 via openalex
- doi:10.1055/s-2001-19136 via openalex
- doi:10.1210/jcem-73-5-925 via openalex
- doi:10.2337/diacare.25.1.55 via openalex
- doi:10.1007/s00125-005-0096-0 via openalex
- doi:10.1016/j.metabol.2007.01.014 via openalex
- doi:10.2337/diacare.23.12.1731 via openalex
- doi:10.1111/j.1748-1716.1993.tb09596.x via openalex
- doi:10.1016/s0140-6736(02)11774-0 via openalex
- doi:10.1056/nejm198909073211004 via openalex
- doi:10.1097/gme.0b013e31803167ab via openalex
- doi:10.2337/diab.45.5.615 via openalex
- doi:10.1001/archinte.1989.00390110045010 via openalex
- doi:10.2337/diabetes.49.12.2094 via openalex
- doi:10.1016/s0092-8674(00)80546-2 via openalex
- doi:10.1111/j.1749-6632.1999.tb07786.x via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-05-11T06:03:29.626429+00:00
License: CC0
· commercial use OK